Elo Mutual Pension Insurance Co Takes $606,000 Position in Exelixis, Inc. (NASDAQ:EXEL)

Elo Mutual Pension Insurance Co bought a new stake in Exelixis, Inc. (NASDAQ:EXEL - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 18,198 shares of the biotechnology company's stock, valued at approximately $606,000.

A number of other hedge funds and other institutional investors also recently bought and sold shares of EXEL. Allspring Global Investments Holdings LLC boosted its position in shares of Exelixis by 82.1% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,562,790 shares of the biotechnology company's stock worth $52,884,000 after acquiring an additional 704,786 shares in the last quarter. Globeflex Capital L P boosted its holdings in Exelixis by 203.8% in the fourth quarter. Globeflex Capital L P now owns 975,151 shares of the biotechnology company's stock valued at $32,473,000 after purchasing an additional 654,200 shares in the last quarter. Caisse DE Depot ET Placement DU Quebec purchased a new position in Exelixis in the third quarter valued at approximately $14,979,000. Raymond James Financial Inc. acquired a new stake in Exelixis during the fourth quarter worth approximately $17,046,000. Finally, Burney Co. purchased a new stake in shares of Exelixis during the 4th quarter worth approximately $12,267,000. 85.27% of the stock is currently owned by institutional investors and hedge funds.

Exelixis Stock Performance

Shares of NASDAQ EXEL traded down $2.11 during trading on Friday, reaching $34.57. The stock had a trading volume of 2,944,993 shares, compared to its average volume of 2,148,851. The stock has a market cap of $9.68 billion, a PE ratio of 19.53, a P/E/G ratio of 1.13 and a beta of 0.57. Exelixis, Inc. has a one year low of $20.14 and a one year high of $40.02. The firm's 50 day moving average price is $35.90 and its two-hundred day moving average price is $33.56.

Remove Ads

Exelixis (NASDAQ:EXEL - Get Free Report) last issued its earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.51 by ($0.03). Exelixis had a return on equity of 23.52% and a net margin of 24.04%. On average, research analysts expect that Exelixis, Inc. will post 2.04 earnings per share for the current year.

Analysts Set New Price Targets

EXEL has been the topic of a number of recent analyst reports. Oppenheimer downgraded shares of Exelixis from an "outperform" rating to a "market perform" rating and dropped their target price for the company from $41.00 to $33.00 in a research report on Friday, January 24th. JMP Securities reaffirmed a "market outperform" rating and set a $41.00 price objective on shares of Exelixis in a report on Thursday, January 23rd. Piper Sandler lifted their target price on Exelixis from $37.00 to $38.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 12th. HC Wainwright reissued a "buy" rating and issued a $40.00 target price on shares of Exelixis in a research report on Thursday, March 27th. Finally, BMO Capital Markets lowered Exelixis from an "outperform" rating to a "market perform" rating and lifted their price target for the stock from $36.00 to $40.00 in a research report on Friday, December 20th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $37.59.

Insider Activity at Exelixis

In other Exelixis news, EVP Patrick J. Haley sold 52,636 shares of the business's stock in a transaction on Monday, February 24th. The stock was sold at an average price of $36.98, for a total transaction of $1,946,479.28. Following the completion of the transaction, the executive vice president now owns 303,310 shares in the company, valued at approximately $11,216,403.80. The trade was a 14.79 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Jack L. Wyszomierski sold 8,768 shares of the stock in a transaction dated Friday, February 28th. The shares were sold at an average price of $37.80, for a total transaction of $331,430.40. Following the completion of the transaction, the director now owns 356,605 shares of the company's stock, valued at $13,479,669. This represents a 2.40 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 140,343 shares of company stock worth $5,177,234 in the last 90 days. 2.85% of the stock is currently owned by company insiders.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.